SPRC (SciSparc) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRC SciSparc Ltd SPRC
39 GF Score
Price $6.58
GF Value $3.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is SciSparc Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SPRC
39GF Score
SciSparc Ltd SPRC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciSparc (SPRC) Overvalued in 2026?

Based on GuruFocus' analysis, SciSparc stock appears to be overvalued. The current stock price of $6.58 is trading 117.2% above its estimated GF Value™ of $3.03. GuruFocus considers SciSparc to be Significantly Overvalued.

Key valuation signals for SPRC:

  • Short Ratio:
  • GF Value™: $3.03 vs. price of $6.58 (117.2% above fair value)
  • GF Score™: 39/100 with 8 warning signs

No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SciSparc Business Description

Address 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score

Get the complete analysis for SPRC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.58
Price
$3.03
GF Value